HUE054342T2 - Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával - Google Patents

Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával

Info

Publication number
HUE054342T2
HUE054342T2 HUE18197286A HUE18197286A HUE054342T2 HU E054342 T2 HUE054342 T2 HU E054342T2 HU E18197286 A HUE18197286 A HU E18197286A HU E18197286 A HUE18197286 A HU E18197286A HU E054342 T2 HUE054342 T2 HU E054342T2
Authority
HU
Hungary
Prior art keywords
preventing
methods
inhibiting binding
treating certain
certain disorders
Prior art date
Application number
HUE18197286A
Other languages
English (en)
Hungarian (hu)
Inventor
Andreas Hohlbaum
Laurent Audoly
Beverly Koller
Original Assignee
Pieris Pharmaceuticals Gmbh
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pieris Pharmaceuticals Gmbh, Astrazeneca Ab filed Critical Pieris Pharmaceuticals Gmbh
Publication of HUE054342T2 publication Critical patent/HUE054342T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HUE18197286A 2011-12-13 2012-12-12 Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával HUE054342T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161570018P 2011-12-13 2011-12-13

Publications (1)

Publication Number Publication Date
HUE054342T2 true HUE054342T2 (hu) 2021-08-30

Family

ID=47552959

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18197286A HUE054342T2 (hu) 2011-12-13 2012-12-12 Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával
HUE12813295A HUE042720T2 (hu) 2011-12-13 2012-12-12 Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE12813295A HUE042720T2 (hu) 2011-12-13 2012-12-12 Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén

Country Status (13)

Country Link
US (6) US9572863B2 (cg-RX-API-DMAC7.html)
EP (3) EP3842058B1 (cg-RX-API-DMAC7.html)
JP (5) JP6163162B2 (cg-RX-API-DMAC7.html)
CN (2) CN109432402B (cg-RX-API-DMAC7.html)
AU (1) AU2012350660B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858962C (cg-RX-API-DMAC7.html)
DK (2) DK2790719T3 (cg-RX-API-DMAC7.html)
ES (2) ES2710384T3 (cg-RX-API-DMAC7.html)
HU (2) HUE054342T2 (cg-RX-API-DMAC7.html)
PL (2) PL3453400T3 (cg-RX-API-DMAC7.html)
SG (2) SG11201402992SA (cg-RX-API-DMAC7.html)
TR (1) TR201901826T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013087660A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902679B2 (ja) * 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
WO2013087660A1 (en) 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
CA2949405C (en) * 2014-05-22 2023-08-01 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
CN108348573A (zh) 2015-07-15 2018-07-31 皮里斯制药有限公司 Lag-3特异性的新型蛋白
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3571219A1 (en) 2017-01-18 2019-11-27 Pieris Pharmaceuticals GmbH Lipocalin muteins with binding affinity for lag-3
KR20250057131A (ko) 2017-04-21 2025-04-28 엘랑코 유에스 인코포레이티드 수의학 용도를 위한 il4/il13 수용체 분자
CN111514292B (zh) 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
WO2020201038A1 (en) 2019-03-29 2020-10-08 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
EP3946415A1 (en) * 2019-03-29 2022-02-09 Astrazeneca AB Lipocalin mutein for treatment of asthma
TW202241490A (zh) 2020-12-18 2022-11-01 瑞典商阿斯特捷利康公司 用於治療氣喘之脂質運載蛋白突變蛋白乾粉配製物
CN115414467B (zh) * 2022-10-14 2023-06-06 中国人民解放军陆军军医大学第二附属医院 载脂蛋白d在制备治疗脑出血药物中的用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
DE4425255A1 (de) 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6446467B1 (en) 1997-07-29 2002-09-10 Physical Optics Corporation Monolithic glass light shaping diffuser and method for its production
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
EP1658308A1 (en) 2003-08-25 2006-05-24 Pieris ProteoLab AG Muteins of a bilin-binding protein with affinity for a given target
RU2389796C2 (ru) 2003-08-29 2010-05-20 Аэровэнс, Инк. Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
WO2007107563A2 (en) 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
MX2009001203A (es) * 2006-08-01 2009-06-01 Pieris Ag Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
CN101784280A (zh) * 2007-07-11 2010-07-21 艾罗文斯公司 药物多肽干粉气溶胶制剂及制备方法
JP5902679B2 (ja) 2010-06-08 2016-04-13 ピエリス アーゲーＰｉｅｒｉｓ Ａｇ ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
WO2013087660A1 (en) * 2011-12-13 2013-06-20 Pieris Ag Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Also Published As

Publication number Publication date
JP7441589B2 (ja) 2024-03-01
EP3453400B1 (en) 2021-01-20
CA2858962A1 (en) 2013-06-20
US10398754B2 (en) 2019-09-03
CN103998053B (zh) 2018-11-02
TR201901826T4 (tr) 2019-03-21
JP2017149733A (ja) 2017-08-31
EP3453400A1 (en) 2019-03-13
AU2012350660A1 (en) 2014-07-03
EP2790719B1 (en) 2018-11-21
US20210145934A1 (en) 2021-05-20
US9572863B2 (en) 2017-02-21
US10857202B2 (en) 2020-12-08
WO2013087660A1 (en) 2013-06-20
US20140357548A1 (en) 2014-12-04
HUE042720T2 (hu) 2019-07-29
JP6163162B2 (ja) 2017-07-12
US20190030121A1 (en) 2019-01-31
AU2012350660B2 (en) 2018-01-25
US11382951B2 (en) 2022-07-12
US20200009223A1 (en) 2020-01-09
CN109432402B (zh) 2022-04-29
PL2790719T3 (pl) 2019-05-31
EP3842058B1 (en) 2023-08-23
SG10201604566QA (en) 2016-07-28
US20230021168A1 (en) 2023-01-19
US20170112900A1 (en) 2017-04-27
CN103998053B9 (zh) 2020-07-21
DK2790719T3 (en) 2019-02-11
SG11201402992SA (en) 2014-07-30
DK3453400T3 (da) 2021-04-06
CN109432402A (zh) 2019-03-08
EP2790719A1 (en) 2014-10-22
JP2019116499A (ja) 2019-07-18
JP2020164532A (ja) 2020-10-08
JP6889201B2 (ja) 2021-06-18
JP2022084854A (ja) 2022-06-07
ES2710384T3 (es) 2019-04-24
JP2015505303A (ja) 2015-02-19
PL3453400T3 (pl) 2021-08-09
CA2858962C (en) 2023-09-05
ES2863410T3 (es) 2021-10-11
EP3842058A1 (en) 2021-06-30
US10016483B2 (en) 2018-07-10
JP6725447B2 (ja) 2020-07-15
CN103998053A (zh) 2014-08-20

Similar Documents

Publication Publication Date Title
SG11201402992SA (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
IL311262B2 (en) Methods for treating or preventing cholesterol-related disorders
IL226401A0 (en) Methods for treating disorders related to @fgfBA
ZA201606957B (en) Biguanide compositions and methods of treating metabolic disorders
IL282128A (en) Methods for treating overweight and obesity
ZA201308421B (en) Compositions uses and methods for treatment of metabolic disorders and diseases
PT2776567T (pt) Composições e métodos para o tratamento de citomegalovírus
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201305783B (en) Composition and methods for treating cardiovascular diseases
ZA201307649B (en) Methods and compositions for treatment of attention deficit disorder
IL231447B (en) Methods and preparations for regulating transgene expression
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
PH12013501969A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
EP2675460A4 (en) TREATMENT OF FAT TISSUE UNDER CHIN
PT2772486T (pt) Inibidor de quinase e método para tratamento de doenças relacionadas
IL230433A0 (en) Pain management methods
IL232190A0 (en) A method for treating inflammatory diseases by anti-m-csf antibodies
EP2670243A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA
IL229705A0 (en) Methods for the treatment or prevention of neurological diseases
EP2919856A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS
ZA201309109B (en) Methods of treating biomass
IL227703A0 (en) Converted Ometic Sulfur Compounds and Methods of Using Them
GB201119458D0 (en) Compositions for treatment of sleep disorders
IL227921A0 (en) Methods for prognosis and treatment of inflammatory disorders
GB201101773D0 (en) Treatment of inflammatory disorders